1463. Bucladesine

Nomenclature

CAS number: 362-74-3
N-(1-Oxobutyl)adenosine cyclic 3′,5′-(hydrogen phosphate) 2′-butanoate; N-(9-β-d-ribofuranosyl-9H-purin-6-yl)butyramide cyclic 3′,5′-(hydrogen phosphate) 2′-butyrate; N6,2′-O-dibutyryladenosine 3′,5′-cyclic monophosphate; N6,2′-O-dibutyryl cAMP; DBcAMP.
C18H24N5O8P; mol wt 469.39.
C 46.06%, H 5.15%, N 14.92%, O 27.27%, P 6.60%.

Description and references

Vasodilating cyclic nucleotide derivative which can permeate the cell membrane. Mimics the action of endogenous cyclic AMP, q.v. Prepn: Th. Posternak et al., Biochim. Biophys. Acta 65, 558 (1962); O. Nagase et al., JP Kokai 76 113896, C.A. 86, 140409r (1977); T. Hirayama et al., JP Kokai 77 39698; JP 77 39699, C.A. 87, 136330m-136331n (1977) (1976, 1977, 1977 all to Daiichi Seiyaku). Pharmacology: H. S. White et al., Eur. J. Pharmacol. 57, 107 (1979); J. D. Johnson et al., ibid. 91, 343 (1983); N. Bondar et al., J. Physiol. 355, 33 (1984). Clinical trial in congestive heart failure: S. Matsui et al., Am. J. Cardiol. 51, 1364 (1983); after cardiopulmonary bypass surgery: T. Yoshitake et al., Prog. Clin. Biol. Res. 111, 211 (1983).

Chemical structure

Derivative

Sodium salt.

Nomenclature

CAS number: 16980-89-5
DC-2797; Actosin (Daiichi Seiyaku).
C18H23N5NaO8P; mol wt 491.37.
C 44.00%, H 4.72%, N 14.25%, Na 4.68%, O 26.05%, P 6.30%.

Derivative

Barium salt.

Nomenclature

CAS number: 18837-96-2
C36H46BaN10O16P2; mol wt 1074.08.
C 40.26%, H 4.32%, Ba 12.79%, N 13.04%, O 23.83%, P 5.77%.

Properties

uv max (ethanol-0.5M ammonium acetate, 5:2) 270 nm.

Therapeutic Category

Cardiotonic.

Keywords

Cardiotonic